Advanced Search

Submit Online

Volume 14, Issue 8, August 2022

Articles

The single-sample network module biomarkers (sNMB) method reveals the pre-deterioration stage of disease progression
Jiayuan Zhong, Huisheng Liu, Pei Chen
J Mol Cell Biol, Volume 14, Issue 8, August 2022, mjac052, https://doi.org/10.1093/jmcb/mjac052
Abstract | Full Text 
U1 snRNP proteins promote proximal alternative polyadenylation sites by directly interacting with 3′ end processing core factors
Zhijie Hu, Mengxia Li, Zhanfeng Huo, Liutao Chen, Susu Liu, Ke Deng, Xin Lu, Shangwu Chen, Yonggui Fu, Anlong Xu
J Mol Cell Biol, Volume 14, Issue 8, August 2022, mjac054, https://doi.org/10.1093/jmcb/mjac054
Abstract | Full Text 
Knockdown of hepatocyte Perilipin-3 mitigates hepatic steatosis and steatohepatitis caused by hepatocyte CGI-58 deletion in mice
Xinyu Bao, Xiaogen Ma, Rongfeng Huang, Jianghui Chen, Haoran Xin, Meiyu Zhou, Lihua Li, Shifei Tong, Qian Zhang, Guanghou Shui, Fang Deng, Liqing Yu, Min-Dian Li, Zhihui Zhang
J Mol Cell Biol, Volume 14, Issue 8, August 2022, mjac055, https://doi.org/10.1093/jmcb/mjac055
Abstract | Full Text 
Acetylation of Nup62 by TIP60 ensures accurate chromosome segregation in mitosis
Hameed Akbar, Jun Cao, Dongmei Wang, Xiao Yuan, Manjuan Zhang, Saravanakumar Muthusamy, Xiaoyu Song, Xu Liu, Felix Aikhionbare, Xuebiao Yao, Xinjiao Gao, Xing Liu
J Mol Cell Biol, Volume 14, Issue 8, August 2022, mjac056, https://doi.org/10.1093/jmcb/mjac056
Abstract | Full Text 

Review

Anti-cancer mechanisms of action of therapeutic alternating electric fields (tumor treating fields [TTFields]) 
Shadi Shams, Chirag B. Patel
J Mol Cell Biol, Volume 14, Issue 8, August 2022, mjac047, https://doi.org/10.1093/jmcb/mjac047
Abstract | Full Text 

Research Advance

Rewiring the transcriptional circuitries in cancer by endogenous retroviruses
Li Li, Yinshuang Li, Lu Lv, Kai Yuan
J Mol Cell Biol, Volume 14, Issue 8, August 2022, mjac053, https://doi.org/10.1093/jmcb/mjac053
Abstract | Full Text 

< Previous

Next >

Cover: Tumor treating fi elds (TTFields) is the latest FDA-approved therapy for patients with glioblastoma, a lethal form of brain cancer. The mechanisms of action of TTFields in cancer include, but are not limited to, cellular disruption causing abnormal cell division, autophagy, apoptosis, reduced invasion/migration, and increased DNA damage, all of which ultimately lead to increased cancer cell death and decreased cancer cell survival and growth. This image was contributed by Jim Strommer and created with BioRender.com. See mjac047 by Shams and Patel for details.